| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Jiang,Wei-Feng | Chairman | 1.79% | |
| Wang,Xian-Zhi | Director | 1.93% | |
| Xu,Yuan-Hong | Director | 0.50% | |
| CHINA CHEMICAL & PHARMACEUTICAL CO., LTD. | Director | 4.54% | |
| Yun Cheng Investment Corporation | Director | 4.89% | |
| Chen,Zhi-Long | Director | 0.66% | |
| Wu,Chao-Tong | Independent Director | 0.00% | |
| Hong,Qi-Chang | Independent Director | 0.00% | |
| Fu,Zu-Sheng | Independent Director | 0.00% |
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 14 | 18 | - |
| Operating cost | - | - | - |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 14 | 18 | - |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 14 | 18 | - |
| Operating expenses | 88,277 | 140,505 | 121,746 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -88,263 | -140,487 | -121,746 |
| Non-operating income and expenses | 11,029 | 12,935 | 10,457 |
| Net profit (loss) before tax | -77,234 | -127,552 | -111,289 |
| Income tax expense (benefits) | 0 | -4 | 436 |
| Net profit (loss) of ongoing business for the current period | -77,234 | -127,548 | -111,725 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -77,234 | -127,548 | -111,725 |
| Other comprehensive profit (loss), net | -1,081 | 1,081 | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -78,315 | -126,467 | -111,725 |
| Net profit (loss) attributable to owners of parent company | - | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | -1 | -2 | -2 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | - | - | - |
| Net cash inflows (outflows) from investing activities | - | - | - |
| Net cash inflow (outflow) from financing activities | - | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | - | - | - |
| Beginning balance of cash and cash equivalents | - | - | - |
| Ending balance of cash and cash equivalents | - | - | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 248,200 | 210,672 | 279,031 |
| Non-current asset | 58,181 | 83,909 | 63,651 |
| Total asset | 306,381 | 294,581 | 342,682 |
| Current liability | 17,709 | 19,558 | 15,705 |
| Non-current liability | 4,579 | 5,950 | 12,630 |
| Total liability | 22,288 | 25,508 | 28,335 |
| share capital | 649,579 | 640,052 | 575,959 |
| Equity - secruity token | - | - | - |
| capital reserve | 121,882 | 46,905 | 45,525 |
| retained earning | -468,246 | -391,035 | -263,487 |
| Other equity | -19,122 | -26,849 | -43,650 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | - | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 284,093 | 269,073 | 314,347 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 65,473 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 4 | 4 | 5 |
